A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	Recruiting	Phase 1	2026-09-18		NCT06859762

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
MediLink Therapeutics (Suzhou) Co., Ltd.	24

21 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cancer Hospital of Shandong First Medical University	Jinan	China	20
Cleveland Clinic Taussig Cancer Institute	Cleveland	United States	8
Columbia University Irving Medical Center	New York	United States	234
Duke University Medical Center (DUMC)	Durham	United States	3
Harbin Medical University Cancer Hospital	Harbin	China	102
Karmanos Cancer Institute	Detroit	United States	153
Mayo Clinic Arizona	Phoenix	United States	55
Peking Union Medical College Hospital	Beijing	China	1
Ruijin Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	China	45
The First Affiliated Hospital of China Medical University	Shenyang	China	21
The First Affiliated Hospital of Nanchang University	Nanchang	China	109
The Sixth Affiliated Hospital of Sun Yat-sen University	Guangzhou	China	34
The University of Kansas Cancer Center (KUCC)	Kansas City	United States	1
The University of Texas MD Anderson Cancer Center	Houston	United States	207
Tianjin Medical University Cancer Institute & Hospital	Tianjin	China	58
UCLA Hematology/Oncology - Santa Monica	Santa Monica	United States	15
University of Cincinnati Medical Center	Cincinnati	United States	83
University of Wisconsin Health - UW Carbone Cancer Center	Madison	United States	1
UT Health San Antonio - Mays Cancer Center	San Antonio	United States	2
Yale Cancer Center	New Haven	United States	15
Zhejiang Cancer Hospital	Hangzhou	China	164

Clinical trials